NordestgaardBGChapmanMJHumphriesSE. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur Heart J2013; 34: 3478–3490a.
2.
HammondEWattsGFRubinsteinY. Role of international registries in enhancing the care of familial hypercholesterolaemia. Int J Evid Based Healthc2013; 11: 134–139.
3.
Vallejo-Vaz A, Akram A, Kondapally Seshasaic S, et al. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies. Atheroscler Suppl. 2016; in press.
4.
WattsGFDingPYGeorgeP. Translational research for improving the care of familial hypercholesterolemia: The ‘Ten Countries Study’ and beyond. J Atheroscler Thromb2016; 23: 891–900.
5.
WattsGFGiddingSWierzbickiAS. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol2014; 171: 309–325.
6.
MundalLIglandJOseL. Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992–2013. Eur J Prev Cardiol2017; 24: 137–144.
7.
MundalLSarancicMOseL. Mortality among patients with familial hypercholesterolemia: A registry-based study in Norway, 1992–2010. J Am Heart Assoc2014; 3: e001236–e001236.
8.
NanchenDGencerBAuerR. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J2015; 36: 2438–2445.
9.
NanchenDGencerBMullerO. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation2016; 134: 698–709.
10.
RallidisLSTriantafyllisASTsirebolosG. Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins. Atherosclerosis2016; 249: 17–21.
11.
MortensenMBKulenovicIKlausenIC. Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: Prevalence, risk factor burden, and impact on age at presentation. J Clin Lipidol2016; 10: 1145–1152 e1.
12.
RerupSABangLEMogensenUM. The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction. Am Heart J2016; 181: 35–42.
13.
KheraAVWonHHPelosoGM. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol2016; 67: 2578–2589.
14.
KroghHWMundalLHolvenKB. Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death. Eur Heart J2016; 37: 1398–1405.
15.
PangJPoulterEBBellDA. Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. J Clin Lipidol2015; 9: 703–708.
16.
PijlmanAHHuijgenRVerhagenSN. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in The Netherlands. Atherosclerosis2010; 209: 189–194.
17.
VuorioAWattsGFKovanenPT. Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities. J Clin Lipidol2016; 10: 1278–1279.
18.
VuorioAWattsGFKovanenPT. Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: A new design for living with a high-risk condition?Eur Heart J2016; 37: 1353–1356.
19.
NeilHAHammondTHuxleyR. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: Prospective registry study. BMJ2000; 321: 148–148.
20.
Umans-EckenhausenMADefescheJCSijbrandsEJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet2001; 357: 165–168.
21.
MataNAlonsoRBadimonL. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis2011; 10: 94–94.
22.
O’BrienECRoeMTFrauloES. Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. Am Heart J2014; 167: 342–349.e17.
23.
WongSTaraboantaCFrancisG. The British Columbia Familial Hypercholesterolemia Registry. B C Med J2013; 55: 326–330.
HaralambosKWhatleySDEdwardsR. Clinical experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis2015; 240: 190–196.
26.
PangJLansbergPJWattsGF. International developments in the care of familial hypercholesterolemia: where now and where to next?J Atheroscler Thromb2016; 23: 505–519.
27.
StephensonSHLarrinaga-ShumSHopkinsPN. Benefits of the MEDPED treatment support program for patients with familial hypercholesterolemia. J Clin Lipidol2009; 3: 94–100.
28.
RamaswamiUCooperJHumphriesSE. FH Paediatric Register Steering Group. The UK Paediatric Familial Hypercholesterolaemia Register: Preliminary data. Arch Dis Child2016; In Press, doi:10.1136/archdischild-2015-308570.
29.
Napier KR, Pang J, Lamont L, et al. A web-based registry for familial hypercholesterolaemia. Heart, Lung and Circulation 2016: In Press.
